Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia

Pediatrics

Volumn 132, Issue 5, 2013, Pages

  Williams, Derek J ^a   Hall, Matthew ^b   Shah, Samir S ^c   Parikh, Kavita ^d   Tyler, Amy ^e   Neuman, Mark I ^f   Hersh, Adam L ^g   Brogan, Thomas V ^h   Blaschke, Anne J ^g   Grijalva, Carlos G ⁱ  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b CHILDREN S HOSPITAL ASSOCIATION   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e University of Colorado Denver and Children s Hospital Colorado   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic use; Effectiveness; Pediatrics; Pneumonia

Indexed keywords

AMPICILLIN; BRONCHODILATING AGENT; CEFOTAXIME; CEFTRIAXONE; CORTICOSTEROID; MACROLIDE; OSELTAMIVIR; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT;

ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; INFANT; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PEDIATRIC HOSPITAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HOSPITALIZATION; MULTICENTER STUDY; TRENDS;

AMPICILLIN; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEFTRIAXONE; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; PENICILLINS; PNEUMONIA; RETROSPECTIVE STUDIES;

EID: 84887123129     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-1614     Document Type: Article

References (35)

1. Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53 (7):e25-e76.
2. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4): 701-707. (Pubitemid 38437371)
3. Juvén T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19(4):293-298. (Pubitemid 30213066)
4. Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, populationbased study. Pediatr Infect Dis J. 1998;17 (11):986-991. (Pubitemid 28549416)
5. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
6. Kyaw MH, Lynfield R, Schaffner W, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006; 354(14):1455-1463.
7. Centers for Disease Control Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae- United States, 2006-2007. MMWR. 2008;57(50):1353-1355.
8. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205(3):401-411.
9. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20(9):829-837. (Pubitemid 32880315)
10. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48(11):1596-1600.
11. Hersh AL, Shapiro DJ, Pavia AT, Shah SS. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011; 128(6):1053-1061.
12. Kronman MP, Hersh AL, Feng R, Huang YS, Lee GE, Shah SS. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994-2007. Pediatrics. 2011; 127(3):411-418.
13. Brogan TV, Hall M, Williams DJ, et al. Variability in processes of care and outcomes among children hospitalized with communityacquired pneumonia. Pediatr Infect Dis J. 2012;31(10):1036-1041.
14. Schouten JA, Hulscher ME, Natsch S, Kullberg BJ, van der Meer JW, Grol RP. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: A qualitative study. Qual Saf Health Care. 2007;16(2):143-149. (Pubitemid 46596455)
15. Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA. 2008;299(17):2048-2055. (Pubitemid 351656586)
16. Williams DJ, Shah SS, Myers AM, et al. Identifying pediatric community-acquired pneumonia hospitalizations: Accuracy of administrative billing codes [published online ahead of print July 29, 2013]. JAMA Pediatr. doi: 10.1001/jamapediatrics.2013.186.
17. Feudtner C, Christakis DA, Connell FA. Pediatric deaths attributable to complex chronic conditions: A population-based study of Washington State, 1980-1997. Pediatrics. 2000;106(1 Pt 2):205-209. (Pubitemid 30436857)
18. Rosenbaum PR, Rubin DB. Constructing a control-group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1): 33-38.
19. Ribeiro CF, Ferrari GF, Fioretto JR. Antibiotic treatment schemes for very severe community- Acquired pneumonia in children: A randomized clinical study. Revista Panam Salud Publica. 2011;29(6):444-450.
20. Vuori-Holopainen E, Peltola H, Kallio MJ; SE-TU Study Group. Narrow- versus broadspectrum parenteral antimicrobials against common infections of childhood: A prospective and randomised comparison between penicillin and cefuroxime. Eur J Pediatr. 2000;159(12):878-884.
21. Dinur-Schejter Y, Cohen-Cymberknoh M, Tenenbaum A, et al. Antibiotic treatment of children with community-acquired pneumonia: comparison of penicillin or ampicillin versus cefuroxime. Pediatr Pulmonol. 2013;48(1):52-58.
22. Newman RE, Hedican EB, Herigon JC, Williams DD, Williams AR, Newland JG. Impact of a guideline on management of children hospitalized with communityacquired pneumonia. Pediatrics. 2012;129 (3). Available at: www.pediatrics.org/cgi/content/full/129/3/e597.
23. García-García ML, Calvo C, Pozo F, Villadangos PA, Pérez-Breña P, Casas I. Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J. 2012;31(8):808-813.
24. Esposito S, Daleno C, Prunotto G, et al. Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respi Viruses. 2013;7(1):18-26.
25. Wolf DG, Greenberg D, Shemer-Avni Y, Givon-Lavi N, Bar-Ziv J, Dagan R. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr. 2010;156(1):115-120.
26. Cilla G, Oñate E, Perez-Yarza EG, Montes M, Vicente D, Perez-Trallero E. Viruses in community-acquired pneumonia in children aged less than 3 years old: high rate of viral coinfection. J Med Virol. 2008;80 (10):1843-1849.
27. Hammitt LL, Kazungu S, Morpeth SC, et al. A preliminary study of pneumonia etiology among hospitalized children in Kenya. Clin Infect Dis. 2012;54(suppl 2):S190-S199.
28. Mermond S, Zurawski V, D'Ortenzio E, et al. Lower respiratory infections among hospitalized children in New Caledonia: A pilot study for the Pneumonia Etiology Research for Child Health project. Clin Infect Dis. 2012;54(suppl 2):S180-S189.
29. AHRQ. National estimates on use of hospitals by children from the HCUP Kids' Inpatient Database (KID). 2009. Available at: http://hcupnet.ahrq.gov/ HCUPnet.jsp?Id=F3D2E7DF566C8BCC&Form=SelPAT&JS=Y&Action= %3E%3ENext%3E%3E&-InPatChar=Yes&-InHospChar=Yes&-PatChar= Accessed March 22, 2012.
30. Neuman MI, Hall M, Hersh AL, et al. Influence of hospital guidelines on management of children hospitalized with pneumonia. Pediatrics. 2012;130(5). Available at: www.pediatrics.org/cgi/content/full/130/5/e823.
31. McIntosh KA, Maxwell DJ, Pulver LK, et al. A quality improvement initiative to improve adherence to national guidelines for empiric management of community-acquired pneumonia in emergency departments. Int J Qual Health Care. 2011;23(2):142-150.
32. Smith MJ, Kong M, Cambon A, Woods CR. Effectiveness of antimicrobial guidelines for community-acquired pneumonia in children. Pediatrics. 2012;129(5). Available at: www.pediatrics.org/cgi/content/full/129/5/e1326.
33. Ambroggio L, Thomson J, Kurowski EM, et al. Quality improvement increases appropriate antibiotic prescribing for childhood community acquired pneumonia. Pediatrics. 2013;131(5). Available at: www.pediatrics.org/cgi/content/full/131/ 5/e1623.
34. Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: A randomized controlled trial. Arch Intern Med. 2012;172(12):922-928.
35. Lorgelly PK, Atkinson M, Lakhanpaul M, et al. Oral versus i.v. antibiotics for community-acquired pneumonia in children: A cost-minimisation analysis. Eur Respir J. 2010;35(4):858-864.